LBA49Neoadjuvant nivolumab (N) or nivolumab plus ipilimumab (NI) for resectable non-small cell lung cancer (NSCLC). (23rd October 2018) - Cascone, T; William, W N; Weissferdt, A; Leung, C H; Federico, L; Haymaker, C; Bernatchez, C; Fossella, F V; Mott, F E; Papadimitrakopoulou, V A; Byers, L; Lam, V K; et al.